Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial

By afschroeder • February 18, 2026

DeVore AD, Majmudar M, Etters L, Xie J, Hao C, Lam PH, Hernandez AF, Fonarow GC, Desai AS. Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial. Circ Heart Fail. 2026 Feb;19(2):e013231. doi: 10.1161/CIRCHEARTFAILURE.125.013231. Epub 2025 Dec 3. PMID: 41332416.

Tags: Cardiology/Epi, drug therapy, heart failure, implementation science, Publications, quality improvement, technology

Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status

Lu F, Ahmed AA, Zhang S, Raman VK, Patel SS, Vargas JD, Fonarow GC, Heidenreich PA, Cleland JGF, Anker SD, Böhm M, Metra M, Zile[...]

Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes

Andrade-Bucknor S, Barforoshi S, Le DE, Lyubarova R, Chung J. Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis[...]

Transthyretin Cardiac Amyloidosis in an Older Athlete

O'Brien D, Reiss RA. Transthyretin Cardiac Amyloidosis in an Older Athlete. Cureus. 2026 Jun 29;18(6):e111747. doi: 10.7759/cureus.111747. PMID: 42534173; PMCID: PMC13419844.